T he Agency for Healthcare Research and Quality (AHRQ) recently ranked sepsis as the most expensive condition treated in US hospitals with estimated costs exceeding $20 billion dollars. 1, 4 Additionally, sepsis is common in hospitalized surgical patients; it occurs 10 times more frequently than pulmonary embolism and myocardial infarction combined. 2 Improved early care over the past decade has decreased in-hospital mortality from severe sepsis/septic shock (SS/SS) from over 35% to less than 15%. 2 Unfortunately, many early survivors now progress to a state of chronic critical illness [CCI; defined by intensive care unit (ICU) stays !14 d], 8, 9, 5 and a substantial portion of these individuals develop persistent inflammation, immunosuppression, and catabolism syndrome (PICS), for which current interventions are ineffective. 6 These patients are often discharged to long-term acute care (LTAC) facilities and suffer indolent death. 5, 7 CCI after SS/SS has surprisingly similar metabolic, immunologic, and phenotypic manifestations to that of patients with advanced cancer. 8 Central to the immunologic response in chronic sepsis and cancer is the expansion of myeloid-derived suppressor cells (MDSCs), which is integral to the ''emergency myelopoietic'' host response that is aimed at preserving innate immunity.
Myeloid-derived suppressor cells are a heterogeneous group of immature myeloid cells, and their expansion may be protective in the short term. 9 They are poor phagocytes and can prevent overactivation of the immune system by secreting interleukin (IL)-10 or tumor growth factor-b. However, their prolonged presence can induce persistent inflammation (via nitric oxide, myeloperoxidase, and reactive oxygen species production), and cause immunosuppression (via inhibition of T-cell proliferation, elaboration of anti-inflammatory cytokines, and poor antigen presentation). 6, 10, 11 MDSCs are commonly reported in cancer, and modulating MDCS is now a vital component in multimodality therapy offering prolonged relief for cancers with traditionally dismal outcomes. 12, 13 However, the role of MDSCs in the host response to SS/SS is not well-defined. 3, 6, 14 In the laboratory, we modeled chronic sepsis and were the first to observe MDSC expansion after sepsis in rodents. 15 Although prior studies have displayed MDSC expansion after human sepsis, they were limited to the acute phase after sepsis and did not examine the potential role that MDSCs play in the adverse clinical outcomes after sepsis. 16, 17 The specific aims of the current study, therefore, were to: determine whether the expansion of 
METHODS

Patient Selection
This 3-year observational study of surgical patients ended in January 2015. The cohort consists of SS/SS patients in the surgical ICUs at UFHealth in Gainesville, Florida. SS/SS was defined by the American College of Chest Physicians/Society of Critical Care Medicine Conference criteria. 18 Patients aged above 18 years were included. Patients were excluded if their expected survival was less than 48 hours, they had severe head injury, were receiving chronic corticosteroid or immunosuppressive therapies, or if they were transferred from another hospital. The study was approved by the UFHealth Institutional Review Board, and signed informed consent was obtained from the subject or their legally appointed representative. Informed consent was also obtained from healthy control (HC) subjects (n ¼ 18) for blood sampling.
Data and Sample Collection
Clinical and laboratory variables were either uploaded directly into the REDCap electronic case report form from the Epic electronic medical record or entered manually. Blood was collected within 12 hours of diagnosis of SS/SS and on days 1, 4, 7, 14, 21, and 28, or until discharge from the ICU or death.
Phenotypic Analysis
Whole blood was stained using antibodies as previously described. 19 MDSCs were characterized as CD33 þ CD11b þ Human Leukocyte Antigen (HLA)-DR À/low ; subsets of monocytic-MDSCs were classified as CD14 þ and granulocytic-MDSCs were classified as CD14 À CD15 þ (Supplemental Fig. 1 , http://links.lww.com/SLA/ B25). Cells were analyzed using LSRII Flow Cytometer (Becton Dickinson). MDSC populations were also evaluated for their IL-4Ra expression. Total leukocyte numbers were determined from clinical laboratory measurements in the SS/SS patients.
Cell Sorting and T-cell Suppression
Myeloid-derived suppressor cells were enriched as CD33
HLA-DR
À/low by cell sorting (FACSAria, Becton Dickinson). Nucleic acids were extracted from enriched MDSCs as previously described.
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CD3
þ T cells were isolated from HC subjects with the Negative Pan T-cell Isolation Kit (Miltenyi, San Diego, CA) and stained with Cell Trace Violet (Life Tech, Grand Island, NY). MDSCs and stained T cells were counted, and 10 6 cells were plated at a 2:1, 1:1, and 0.5:1 MDSC-to-T-cell ratio, and stimulated at a 1:1 ratio with Human T-Activator CD3/CD28 Dynabeads (LifeTech) and IL-2 (LifeTech). After 4 days of culture at 378 C and 5% CO 2 , cells were stained with PE-CD4 and FITC-CD8 (Becton Dickinson), and Live/Dead dye-Far Red (LifeTech). CellTrace Violet was measured in viable CD4 þ and CD8 þ T cells.
Cytokine Analysis
T-cell suppression assay supernatants underwent cytokine analysis. Concentrations of IL-4, interferon (IFN)-g, and IL-10 were determined using Milliplex kits (Millipore) on the Luminex MAGpix Multiplex reader.
Genomic Analysis
RNA was extracted from lysates using QIAGEN Rneasy Mini Kit (Qiagen). RNA integrity was assessed with an Agilent 2100 Bioanalyzer (Santa Clara, CA). RNA was labeled using Nugen (NuGEN Technologies, Inc.) Ovation Pico WTA System V2. Resulting cDNA was labeled, fragmented using Nugen Encore Biotin Module, hybridized onto GeneChip Human Transcriptome Array 2.0 (Affymetrix, Santa Clara, CA), and processed as per manufacturer's instructions.
Gene Expression Profile Analysis
Nucleic acids were extracted and mRNA abundance levels were determined using the Affymetrix HTA 2.0 microarray. Extracted RNA from days 7 and 14 in the SS/SS patient cohort underwent genome-wide expression analysis. Data across these days were indistinguishable; therefore, data were pooled. Microarray expression was normalized using RMA as implemented in Partek (Partek Inc, St Louis, MO). Significant genes (P < 0.001) were identified with class prediction tools implemented in BRB-ArrayTools Version: 4.2.1-Stable Release, developed by Richard Simon & BRB-ArrayTools Development Team (http://linus.nci.nih.gov/ BRB-ArrayTools.html). The ability of genes significant at P < 0.001 to distinguish between HC and SS/SS patients was determined using leave-one-out cross-validation studies and Monte-Carlo simulations. Gene Ontology and BioCarta Pathway analysis were conducted using BRB ArrayTools.
Statistical Analysis
Mixed model analysis of longitudinal changes in circulating MDSCs was performed to account for correlations among repeated measurements for each patient. Total and percentage of MDSCs, granulocytic-MDSCs, and monocytic-MDSCs from SS/SS patients were compared with HC subjects. Kruskal-Wallis test was used to compare patients who died within 14 days of ICU admission to those that survived longer than 14 days; survivors were further categorized by their ICU length of stay (LOS) (<14 d or !14 d). Patients with only 1 blood sample collected (n ¼ 2) or that expired within 7 days (n ¼ 5) were excluded, resulting in a total of 67 patients.
Patients were recognized as having 1 of 3 distinct temporal patterns of MDSC expression: ''sustained low,'' ''decreasing,'' or ''sustained high.'' Patients were considered to have a ''sustained low'' MDSC expression pattern if MDSC levels were less than or equal to 30% of live cells and 2 standard deviations (SD) above the control mean, as measured by flow cytometry. Patients with a declining percentage of MDSCs, indicated by a negative slope over time, were classified as ''decreasing'' MDSC pattern. The remaining patients had either persistently elevated MDSCs or an increasing percentage of MDSC as indicated by a positive slope; these patients were categorized as ''sustained high'' MDSCs. These 3 distinct expression patterns were then evaluated to determine their predictive value.
The primary outcome of interest was functional status at discharge and the secondary outcome was the incidence of nosocomial infections as an indicator of adverse in-hospital outcomes. Functional status at the time of discharge was determined to be either ''successful'' or ''poor'' based on disposition placement. Disposition was ''successful'' if patients were discharged to home, an inpatient rehabilitation facility, or a skilled nursing facility (SNF). Discharge to another inpatient hospital, hospice, LTAC, or death were considered to be ''poor'' dispositions. The secondary outcome of interest was the presence of at least 1 site with nosocomial infection.
Multivariate logistic regression models were fit where the MDSC pattern category was the main predictor of interest, adjusting for variables significant in bivariate analysis at 0.1 level among baseline characteristic variables shown in Supplemental Table 1 (http://links.lww.com/SLA/B25). Model discrimination was assessed using the area under the receiver-operating characteristic curve (AUC). Statistical analysis was performed using SAS (v.9.3, Cary, NC).
Using the percentage of MDSCs may underestimate the difference between HC and SS/SS patients, because SS/SS patients often have a leukocytosis. As a sensitivity analysis we also repeated statistical modeling with the absolute number of MDSCs. Previous modeling utilized the percentage of HC MDSCs to define the ''low sustained'' group; however, HC analysis did not include complete blood count, and the absolute number of HC MDSCs could not be calculated. Therefore, we used cubic polynomial models to predict the corresponding log absolute MDSC counts for the ''low sustained'' group. This corresponded to an absolute MDSC count less than 4583 cells/mL and was defined as ''low sustained.'' ''Decreasing'' was again defined as a negative slope indicating a decreasing number of MDSCs, and the remaining patients were categorized as ''sustained high.'' Table 1 (http://links.lww.com/SLA/B25) lists demographics, comorbidities, illness severity, and outcome of the 67 included study patients, of which 26 (39%) were female with a mean age of 60 years. Sixty-two (93%) of these patients had a least 1 comorbid condition, and the median number of comorbidities was 4. The primary infection for the SS/SS cohort was pneumonia (n ¼ 22, (1), and withdrawal of life-sustaining therapy (1). Thirty-five (52%) patients had at least 1 nosocomial infection; the most common infections were pneumonia (n ¼ 22, 33%), blood stream infection (n ¼ 8, 12%), and urinary tract infection (n ¼ 6, 9%). Sixty-one (91%) patients required mechanical ventilation and 11 (16%) patients required dialysis. The median of ventilator-free ICU days was 5 and that of ICU-free days was 2. Thirty-nine (58%) patients were in the ICU for !14 days. Fifty-nine (88%) patients were discharged alive, and their top 3 dispositions included home (n ¼ 19, 33%), LTAC (n ¼ 13, 22%), and SNF (n ¼ 10, 17%). Figure 1A demonstrates that the percentage of MDSCs dramatically increases in SS/SS patients when compared with HC subjects over the 28-day study period. In patients who remained hospitalized for 28 days, MDSC levels remained significantly elevated over the entire ICU stay. Additionally, IL-4Ra, another cell surface marker associated with MDSCs, was significantly elevated at 24 hours and remained elevated through 28 days 20 (Supplemental Fig. 3 , http://links.lww.com/SLA/B25). Figure 1B and C depicts the percentage of circulating granulocytic and monocytic-MDSCs after SS/SS. In HC subjects, the majority of MDSCs are monocytic in nature. After SS/SS, the ratio inverts as the percentage of granulocytic-MDSCs become significantly elevated at all time points when compared with HC subjects. Conversely, the percentage of monocytic-MDSCs was significantly decreased at all time points when compared with HC subjects. Figure 2 demonstrates that anti-CD3/CD28-stimulated HC T cells readily proliferate; however, HC T-cell proliferation is suppressed by MDSCs from SS/SS patients in a dose-dependent fashion as the ratio of SS/SS MDSCs to HC T cells increases ( Fig. 2A) (P < 0.01). When CD4 þ or CD8 þ T cells (identified by cell surface staining) are incubated at a ratio of 2 SS/SS MDSCs to 1 HC T cell, the per cent suppression exceeded greater than 90% in both subpopulations (as compared with T cells in the absence of MDSCs, data not shown). Similar to our work in septic rodents, 21 T cells from SS/SS patients failed to proliferate in response to stimulation, even in the absence of added MDSCs (data not shown). Additionally, Figure 2B illustrates that HC MDSCs produce a dose-dependent suppression of HC T cells, which is not significantly different from SS/SS MDSCs. This suggests that HC MDSCs also have immunosuppressant properties, but are present in much reduced numbers. 
RESULTS
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FIGURE 1.CD14 À CD15 þ ). C, SS/SS patients have a sig- nificant decrease in monocytic-MDSCs (CD33 þ CD11b þ HLA-DR À/low CD15 þ CD14 þ ) com- pared
MDSCs Increase Acutely and Remain Present Chronically in SS/SS Patients
MDSCs Suppress Ex Vivo T-cell Production
MDSCs Suppress T-cell Cytokine Production
Stimulation of T cells via the T-cell receptor is commonly used to evaluate the polarity of their response through their cytokine production (T H1 vs T H2 ). Not surprisingly, T cells from SS/SS patients express significantly lower levels of IFN-g, IL-10, and IL-4 when compared with HC T cells (P < 0.05) (data not shown). Ex vivo, co-cultures of MDSCs from SS/SS patients (2:1 MDSC:T cell) suppress IFN-g, IL-10, and IL-4 production (Fig. 2C) (P < 0.05). Interestingly, the suppression of cytokine production affected both T H1 (IFN-g) and T H2 (IL-10, IL-4) cytokines from HC T cells (Fig. 2C) , and replicated the suppression displayed by T cells isolated from SS/SS patients (data not shown). Figure 3 depicts the gene transcriptional patterns of enriched MDSCs from SS/SS patients and HC subjects. There were 288 probe sets corresponding to 257 genes that had significant differences (P < 0.001) in expression when comparing HC and SS/SS patients. Individual gene analysis of enriched MDSCs from SS/SS patients was consistent with suppressed HLA gene expression (reduced CD74, and HLA-DOA/-DQA1/-DQA2/-DQB/-DRB1/DRB3/-DRB4) and up-regulated arginase-1 (ARG1) expression (P < 0.001). These changes are consistent with decreased antigen presentation and a depletion of arginine-an amino acid essential to T-cell function. 22 Further transcriptomic analysis revealed expected significant upregulation (HP and CYBB) and down-regulation (CCR3) of MDSCassociated immunity genes. Canonical Pathway and Causal Network Analysis further supported these pathway alterations, and also a pattern of simultaneous low-grade inflammation with immune suppression (P < 0.001; Supplemental Fig. 2 , http://links.lww.com/ SLA/B25). Gene Ontology transcriptomic analysis revealed significant increases in the ''nitric oxide (NO) biosynthesis'' and the ''regulation of reactive oxygen species (ROS) production'' pathways, consistent with a chronic inflammatory role for MDSCs, and also decreased ''detection of bacterium,'' consistent with impaired MDSC innate immune function. Severe sepsis/septic shock patient and healthy control subject gene expression. Using a false discovery adjusted probability of <0.001 and a 2-fold difference in expression, the temporal pattern of the expression of the sepsis responsive genes differed between MDSCs from the healthy control (HC) subjects and severe sepsis/septic shock (SS/SS) patients. A, There was a significant difference in the expression of 257 genes between MDSCs isolated from SS/SS patients and HC subjects (P < 0.001). B, Principle component analysis (PCA) of the gene expression from the 257 genes demonstrates the overall differences in the patterns of gene expression. Gene expression patterns from HC subjects (red) are tightly grouped to the right and the SS/SS patients (blue) are tightly grouped to the left. The tight grouping and lack of overlap of data points reflects the significant difference between the 2 groups.
Genomic Analysis
MDSCs are Associated With Adverse In-hospital Outcomes
Healthy Controls SepƟc PaƟents
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MDSCs After Sepsis longer than 14 days had an increased percentage of MDSCs beginning on day 4, whereas those patients with ICU stays less than 14 days had a steady decrease in their MDSC population. The absolute number, rather than the percentage, of MDSCs were reanalyzed as predictors of early death and length of ICU stay. Interestingly, the percentage of MDSCs in the blood was more predictive than the absolute number of MDSCs. Although patients with early mortality (<14 d) had significantly higher percentages of MDSCs, the absolute numbers of MDSCs were similar because of a relative leukopenia in this population (Fig. 5) . When evaluating ICU LOS, however, higher absolute numbers of MDSCs were also predictive of longer ICU LOS at 7 and 10 days, mirroring what was seen when evaluating percentage of MDSCs (data not shown); however, this did not provide pertinent additional information. Table 1A , containing a prediction model for poor disposition, demonstrates that ''sustained high'' MDSC percentages are associated with poor functional status at the time of discharge, as indicated by significantly increased odds of ''poor'' dispositions. Multivariate logistic regression analysis identified septic shock status and APACHE score on admission as independent risk factors; however, the association remained significant after adjustment for APACHE score and septic shock status indicators. In fact, ''sustained high'' MDSC percentages were a strongly predictive model, with an AUC of 0.79 [95% confidence interval (CI) 0.68-0.90] (Table 1A) .
MDSC Pattern is Associated With Incidence of Nosocomial Infection and Patient Discharge Status
Importantly, in Table 1B-a prediction model for nosocomial infection-patients with ''sustained high'' MDSC percentages were also more likely to have at least 1 subsequent nosocomial infection [odds ratio (OR) 6.67, 95% CI 1.32-33.69] compared with patients with ''sustained low'' MDSC percentages (Table 1B) . In addition, patients who developed nosocomial infections had more ventilator days (18 vs 5 d; P < 0.01) longer ICU stays (25 vs 13 d; P < 0.01) and longer total hospital stays (35 vs 15 d; P < 0.01) when compared with those patients who did not develop nosocomial infections. Again, repeating the analysis using absolute numbers of MDSCs, rather than percentage of MDSCs, did not alter the demonstrated association of MDSCs to this outcome (data not shown).
DISCUSSION
Sepsis remains a major unsolved problem and is the most expensive condition treated in US hospitals. There are over 1 million cases of sepsis per year in the United States, accounting for 9% of the overall annual deaths, 23, 24 and septic shock has an estimated mortality of greater than 50%. 2, 25, 26 Additionally, the incidence of sepsis is increasing, especially in the older people, where those who survive the acute phase of sepsis go on to suffer dismal long-term outcomes. 2, 25, 26 Furthermore, despite basic laboratory data and early-phase clinical testing, numerous promising immunomodulatory interventions have uniformly failed in definitive phase III clinical trials. This begs the question of whether we understand, or oversimplify, the underlying pathophysiology. Our comprehension of sepsis has evolved; fulminant death from an overwhelming systemic inflammatory response syndrome response (where blocking early proinflammation made sense) has been replaced by a paradigm of simultaneous inflammation and immune suppression. 5 However, we now recognize that it is the prolonged dysregulation, and the failure to return to immunologic homeostasis that identifies the patients who experience dismal longterm outcomes. 5, 27 Additionally, advances in early recognition and clinical management of SS/SS have decreased in-hospital mortality, 2 with the unfortunate consequence of creating a new phenotype of patients that progress into a futile trajectory of CCI and PICS. 5 The clinical course of PICS is characterized by manageable organ dysfunctions, recurrent nosocomial infections, and dramatic loss of lean body mass despite aggressive nutritional interventions. 5, 7, [28] [29] [30] These patients are often discharged to LTAC facilities where they commonly experience progressive declines in cognitive and functional status, sepsis recidivism requiring rehospitalization, 31 and ultimately suffer an indolent death. 5, 7 Based on our chronic sepsis models and emerging information from other chronic inflammatory diseases, including cancer, 8 we proposed persistent MDSC expansion as a unifying mechanism to explain the chronic inflammation, immune suppression, and catabolism seen in PICS patients. 5, 32, 33 In this study, we have revealed that MDSCs, identified by their cell surface receptor expression of CD33 A, Patients were categorized into 3 MDSC expression patterns: ''sustained low,'' ''decreasing,'' and ''sustained high,'' and as having either poor or successful dispositions. Patients were recognized as having distinct temporal patterns of MDSC expression: ''sustained low'', ''decreasing'', or ''sustained high.'' Patients were considered to have a ''sustained low'' MDSC expression pattern if MDSC levels were less than or equal to 30% of the total leukocyte count. Patients with a declining percentage of MDSCs, as indicated by a negative slope over time, were classified as having ''decreasing'' MDSC pattern. The remaining patients had either persistently elevated MDSCs or an increasing percentage of MDSC as indicated by a positive slope; these patients were categorized as ''sustained high'' MDSC. Patients with ''sustained high'' levels of MDSCs have almost 8 times the odds of having a poor disposition when compared with patients with ''sustained low'' MDSCs. This relationship remains significant after adjustment for APACHE II score and presence of septic shock (OR 7.33). B, Patients with ''sustained high'' levels of MDSCs had almost 7 times the odds of having nosocomial infections when compared with patients with ''sustained low'' MDSCs. Significant association remained after adjustment for age and number of comorbidities (OR 8.4 ). This suggests that high levels of circulating MDSCs may make patients more vulnerable to nosocomial infection during hospitalization. these cells are truly immunosuppressive. Finally, and perhaps most importantly, we have demonstrated that a sustained increased presence of circulating MDSCs is associated with adverse outcomes (increased nosocomial infections, prolonged ICU stays, and poor functional status at discharge) that are consistent with PICS. Of note, we identified different temporal patterns of MDSC expression, rather than just overall numbers at any time point, to better incorporate personalized medicine into our analysis 34 ; this revealed that those patients whose MDSC pattern reflected ''an inability to return to homeostasis after their infection'' were more likely to have an adverse clinical disposition.
The main limitation of this study was that it was performed at a single institution among a limited number of patients. The total number of study participants could be increased by including multiple institutions; however, the level of complexity and required personnel to consistently perform the sophisticated analyses required places limitations on widespread institution participation. Another limitation of this study was incomplete data at later time points as patients were discharged; collection of blood after hospital discharge would allow for a more robust generalizable analysis. Additionally, although we performed multivariate logistic regression analysis, control samples from more aged individuals, 34, 35 and also individuals undergoing minor operations, could have been of use to prevent further confounding variables in the analysis.
In conclusion, we found that circulating MDSCs are persistently increased in surgical patients after SS/SS, functionally immunosuppressive, and associated with adverse long-term outcomes consistent with PICS. These novel observations warrant further confirmative studies. Of note, MDSCs are phenotypically plastic, which allows them a diverse functionality in response to their environmental conditions, but also creates the potential for future immunomodulating therapies. 22 As observed in cancer immunotherapy, 36 targeting MDSCs could become a component in multimodality therapy aimed at reversing detrimental inflammation and immunosuppression after SS/SS to improve currently observed dismal long-term morbidity and mortality. 37 
